# REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)

> **NCT01483560** · PHASE3 · COMPLETED · sponsor: **University of Glasgow** · enrollment: 493 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Metformin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01483560
- **Lead sponsor:** University of Glasgow
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2017-03-19
- **Final completion:** 2017-04-18
- **Target enrollment:** 493 (ACTUAL)
- **Last updated:** 2019-06-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483560, "REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01483560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*